Genomic-guided precision oncology in canine cancer: from comparative genomics to liquid biopsy and molecular monitoring
Open Access
- 1 January 2026
- journal article
- review article
- Published by XMLink in Journal of Veterinary Science
- Vol. 27 (5) , e53
Abstract
Traditional cancer diagnostics in veterinary medicine are limited by invasiveness and insufficient sensitivity for real-time molecular monitoring. This review critically evaluates the clinical applicability of somatic mutation profiling and liquid biopsy technologies to establish an evidence-based, tiered framework for precision oncology in canine patients, with emphasis on veterinary-specific constraints and technology selection. Key somatic biomarkers demonstrate strong clinical utility: BRAF V595E achieves > 80% diagnostic sensitivity in canine urothelial carcinoma and is detectable non-invasively in urine via droplet digital polymerase chain reaction (ddPCR). The multicenter cancer detection in dogs (CANDiD) study demonstrated circulating tumor DNA-based liquid biopsy achieves 54.7% overall sensitivity and 98.5% specificity, though stage I detection remains critically limited at 16.1%, underscoring the current gap for early-stage screening. Minimal residual disease assessment via allele-specific oligonucleotide-PCR and next-generation sequencing enables detection of molecular relapse 42-168 days before clinical manifestation in canine lymphoma. However, analytical variability across platforms, lack of standardized pipelines, and high cost represent significant barriers to routine veterinary application. Genomic-guided oncology offers substantial clinical value for canine cancer management yet requires veterinary-specific validation before broad adoption. Targeted sequencing panels currently represent the optimal balance of cost-effectiveness and clinical utility for most veterinary practitioners, while ddPCR is preferred for longitudinal tracking of known mutations. Liquid biopsy cannot serve as a standalone screening tool at present, but functions as a valuable complementary monitoring approach. Continued canine-specific biomarker research and multicenter data sharing are essential prerequisites for integrating precision medicine into routine veterinary care.Keywords
Funding Information
- Rural Development Administration (PJ01690702)
This publication has 128 references indexed in Scilit:
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2022
- Tumors of the Mammary Gland2016
- Tumors of the Hemolymphatic System2016
- Multigene Panel Testing in Oncology PracticeJAMA Oncology, 2015
- Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and SurvivalTransplantation and Cellular Therapy, 2014
- The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisBreast Cancer Research and Treatment, 2013
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid TransformationCancer Cell, 2013
- Detection of minimal residual disease (MRD) in canine lymphomaComparative Clinical Pathology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classificationVirchows Archiv, 2008